A nanotechnology formulation for glaucoma

January 13, 2014

Researchers have developed a nanocarrier with the capability of sustained release for ocular indications. Specifically, the developed nanocarrier demonstrated sustained efficacy (IOP lowering up to 120 days with a single subconjunctival injection) and proved to be well tolerated in a diseased nonhuman primate model, making it a prime sustained-release nanomedicine candidate for glaucoma therapy. The reasons for both the sustained release and the stability of the latanoprost-loaded liposomes have been elucidated with binding studies and partitioning arguments.  (Nanowerk)